Berberine Supplements: Benefits, Dosage, Side Effects, and the "Nature's Ozempic" Claim
Written by Abdul Rasheed
Abdul Rasheed is the founder and lead editor of Diabetes Knowledge Hub.
A long-time independent researcher of diabetes management and natural health strategies, he leads the site’s content direction, writing, and editorial decisions.
Medical Reviewer Wendy Castle
MPH, RD, LD, CDCES is a Registered Dietitian and Certified Diabetes Care and Education Specialist based in the United States.
She reviews Diabetes Knowledge Hub articles for medical accuracy against current ADA Standards of Care, with expertise in diabetes management, nutrition counseling, and evidence-based nutrition care.
Berberine is a yellow plant alkaloid with a long history of use in traditional Chinese and Ayurvedic medicine. In recent years, it has become one of the most discussed supplements in the metabolic-health space. Social media popularised it as “nature’s Ozempic,” a supposed natural alternative to the GLP-1 medicine semaglutide.
The evidence is more nuanced. Berberine has been studied for blood glucose, lipid levels, body weight, and metabolic markers in women with PCOS, but the strength and consistency of the evidence vary by outcome. Its proposed mechanisms differ from those of GLP-1 medicines, and many marketing claims go beyond what clinical studies have established.
This article examines what berberine supplements are, what clinical research says about their potential benefits and limitations, how they compare with metformin and semaglutide products, the doses used in studies, side effects, drug interactions, and how to assess product quality.
For background on the metabolic condition discussed throughout this guide, see our overview of what insulin resistance is.
What Is Berberine?
Berberine is a natural isoquinoline alkaloid extracted from the roots, rhizomes, and bark of several plants including barberry (Berberis vulgaris), goldenseal (Hydrastis canadensis), Oregon grape (Berberis aquifolium), and tree turmeric (Berberis aristata).
It has a long history of use in traditional medicine for infections, diarrhoea, and inflammatory conditions. Its modern scientific interest is driven by its effects on glucose metabolism, lipid levels, and body weight — properties investigated in clinical trials beginning in the early 2000s, primarily in Chinese populations.
Types of Berberine Supplements: HCL vs Phytosome vs Dihydroberberine
Standard berberine HCL has a known bioavailability challenge: pharmacokinetic studies consistently characterise its oral absorption as very low. This has driven development of enhanced delivery forms with varying levels of clinical evidence.
Form |
Human Absorption Evidence |
Clinical Outcome Evidence |
Key Limitation |
|---|---|---|---|
Berberine HCL
|
Very low and variable oral bioavailability; exposure differs by formulation
|
Strongest — multiple RCTs including Yin et al. 2008, Lan et al. 2015 meta-analysis
|
Most clinical outcome data are for this form; gastrointestinal effects are commonly reported at study doses
|
Berberine Phytosome
|
One pharmacokinetic study (n=12 healthy volunteers) reported ~10× higher total berberine exposure vs. unformulated berberine. Study authors were employees of the manufacturer; specific to their proprietary formulation
|
Limited — single small industry-linked PK study; clinical outcomes not established
|
Manufacturer-linked study; higher absorption not confirmed in independent trials; clinical equivalence not established
|
Dihydroberberine (DHB)
|
One industry-funded crossover pilot (n=5 healthy males) found higher plasma berberine exposure; no significant differences in glucose or insulin responses vs. berberine HCL. Author had an advisory relationship with the manufacturer
|
Very limited — no large RCTs on clinical outcomes
|
Five-participant pilot; author conflict of interest disclosed; equivalent clinical effects at lower doses not established
|
Berberine HCL is the form most directly represented in clinical research. Claims that phytosome or dihydroberberine provide equivalent clinical effects at lower doses have not been established by large, independent outcome trials.
What Are the Benefits of Taking Berberine?
Berberine has been studied for lowering blood glucose and improving some measures of insulin sensitivity, reducing total cholesterol and triglycerides, and improving metabolic markers in women with PCOS. Weight-loss findings are inconsistent, and evidence for cardiovascular or fatty-liver benefits remains insufficient to support berberine as a treatment for those conditions.
Blood Sugar Control and Insulin Resistance
The largest body of clinical research on berberine concerns blood-glucose measures, although the certainty of the evidence is limited by study quality, heterogeneity, and the populations studied. A 2008 pilot trial published in Metabolism assigned 36 newly diagnosed adults with type 2 diabetes to berberine 500 mg three times daily or metformin 500 mg three times daily for three months [1]. The berberine group’s HbA1c fell from approximately 9.5% to 7.5%. This was a small, short-term pilot study—not a large non-inferiority trial—and its result should not be generalised to all patients with type 2 diabetes.
A 2015 meta-analysis of 27 RCTs and 2,569 participants by Lan et al. found that berberine was associated with improvements in fasting glucose, 2-hour postprandial glucose, and HbA1c compared to placebo in certain comparisons [2]. However, the authors acknowledge limitations in the methodological quality of included studies and note that some comparisons showed a tendency towards lower glucose measures rather than a firmly established effect across all analyses. A 2021 review assessed by the NIH National Center for Complementary and Integrative Health (NCCIH) covered 46 studies involving 4,158 participants [14]. NCCIH notes important limitations: substantial variation in results, predominantly Chinese study populations, and poor methodological quality in several included studies. This context matters for interpreting the findings.
Proposed mechanisms include AMPK-related signalling and changes in insulin-receptor expression. Experimental studies have also investigated GLUT4 transporter activity and effects on hepatic glucose metabolism, but much of this mechanistic evidence comes from cellular or animal research; the relative contribution of these pathways in humans remains uncertain [12,28]. A clinical study reported changes in insulin-receptor expression in people with type 2 diabetes [12].
For more background on the condition and how insulin resistance is assessed, read our guides to type 2 diabetes and the insulin resistance test.
Cholesterol, LDL, HDL, and Triglycerides
Mechanistic research suggests that berberine may increase hepatic LDL-receptor expression by stabilising LDL-receptor mRNA, potentially enhancing the liver’s clearance of LDL from the bloodstream. Kong et al. (2004) described this mechanism, which differs from the HMG-CoA reductase inhibition produced by statins [3]. An earlier three-month clinical study in 116 people with type 2 diabetes and dyslipidaemia reported improvements in lipid measures with berberine 1,000 mg daily [10]. However, clinical evidence has not consistently demonstrated significant LDL reductions with berberine alone; the 2024 meta-analysis discussed below did not find a statistically significant LDL reduction for berberine alone [8].
A 2024 systematic review and meta-analysis by Hernandez et al. published in the Journal of Dietary Supplements examined 41 randomised trials and 4,838 patients [8]. An important distinction emerged: berberine alone did not show statistically significant reductions in LDL cholesterol compared to placebo or routine treatment — confidence intervals crossed zero. However, berberine significantly reduced total cholesterol and triglycerides. The study also examined combination products involving red yeast rice and Silybum marianum (milk thistle). Heterogeneity across studies was extremely high (I² >72%), which limits firm conclusions.
These findings mean the LDL-lowering claims often made for berberine as a standalone supplement are not consistently supported by this large meta-analysis. Total cholesterol and triglyceride reductions appear more robust. Berberine has not been proven to reduce cardiovascular events (heart attacks, strokes) the way statins have.
Evidence for berberine improving HDL cholesterol is mixed and less consistent. Some trials report modest HDL improvements; others do not. This should be presented to patients as uncertain.
Berberine for Weight Loss and Body Composition
Some meta-analyses report modest weight changes with berberine, but the findings are inconsistent. A 2020 meta-analysis by Asbaghi et al. of 12 RCTs reported an average body-weight reduction of approximately 2.07 kg and a waist-circumference reduction of approximately 1.08 cm compared with control [6]. A separate 2020 meta-analysis by Amini et al., also including 12 randomised trials, did not find significant reductions in body weight, BMI, or waist circumference, although it reported a reduction in waist-to-hip ratio [5]. These differing results make the size and reliability of any weight effect uncertain.
A 2026 randomised clinical trial published in JAMA Network Open by Lei et al. (n=337 participants with obesity and metabolic-associated steatotic liver disease who did not have diabetes) tested berberine 1,000 mg daily for six months [19]. Both the berberine and placebo groups experienced some weight reduction during the trial. However, berberine produced no significant additional benefit compared to placebo: there were no significant between-group differences in visceral adipose tissue, liver fat, body weight, BMI, or waist circumference. The trial found no significant between-group differences in HbA1c, fasting plasma glucose, 2-hour postprandial glucose, or HOMA-IR. Exploratory reductions in LDL cholesterol, ApoB, and hs-CRP were observed, but these secondary and exploratory findings were not adjusted for multiple comparisons and should not be interpreted as definitive treatment effects.
The weight reductions reported in some berberine studies are substantially smaller than those reported in obesity-dose semaglutide trials. These are cross-trial comparisons, not head-to-head evidence.
PCOS (Polycystic Ovary Syndrome)
Berberine has been studied in women with PCOS, a condition commonly associated with insulin resistance. In a three-month randomised study of 89 women, participants received berberine plus cyproterone acetate, metformin plus cyproterone acetate, or placebo plus cyproterone acetate [4]. The study reported changes in several metabolic and hormonal measures. It was not designed as a formal non-inferiority trial, so it does not establish that berberine is therapeutically equivalent to metformin. Larger controlled studies are needed to clarify its role.
A subsequent systematic review and meta-analysis of 12 randomised trials by Xie et al. (2019) found no solid evidence that berberine improves live birth or other major reproductive outcomes in women with PCOS [9]. It is important to distinguish between: improvements in metabolic markers (more consistent evidence); improvements in androgen measurements and menstrual patterns (more limited evidence); and improved fertility and live birth outcomes (not established). Berberine is not a fertility treatment.
For practical nutrition information related to this condition, see our guide to a PCOS insulin resistance diet.
Berberine and Cardiovascular Health
A randomised clinical trial by Zeng et al. (2003) published in the American Journal of Cardiology involving 156 patients with congestive heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy found that berberine supplementation alongside standard therapy reduced fatigue and improved ejection fraction [7]. This is supporting evidence worth acknowledging, but a single historical trial of this size is not sufficient to establish berberine as a proven general cardiovascular treatment. No cardiovascular outcomes trials comparable to those conducted for statins or GLP-1 drugs have been completed for berberine.
Berberine and Fatty Liver Disease (MASLD/NAFLD)
A 2024 meta-analysis of 10 RCTs involving 811 people with NAFLD reported improvements in several liver enzymes and metabolic markers. However, the authors noted that clinical evidence remained inconclusive, outcomes showed heterogeneity, and many included studies evaluated berberine as an adjunct to other interventions [27]. A larger 2026 randomised trial in 337 adults with obesity and MASLD found no significant between-group reduction in liver fat after six months of berberine 1,000 mg daily [19]. Taken together, these findings do not establish berberine as an effective treatment for fatty liver disease.
Is Berberine Like Ozempic? Comparing the Mechanisms
The “nature’s Ozempic” label became popular on social media because berberine has been studied for blood glucose and weight-related outcomes. The comparison is misleading: berberine is a plant alkaloid supplement, whereas semaglutide is a prescription GLP-1 receptor agonist. They have different mechanisms, different evidence bases, and different magnitudes of effect.
In the United States, Ozempic is a semaglutide injection used to improve glycaemic control in adults with type 2 diabetes and has additional cardiovascular- and kidney-risk-reduction indications for eligible patients [22]. Wegovy is a semaglutide product with indications that include chronic weight management in eligible adults and adolescents, cardiovascular risk reduction in certain adults, and—under accelerated approval—treatment of noncirrhotic MASH with moderate-to-advanced fibrosis in eligible adults [24]. The 14.9% average weight reduction commonly cited comes from the STEP 1 trial of Wegovy 2.4 mg weekly in adults with overweight or obesity without diabetes [13], not from the standard Ozempic diabetes regimen. The FDA approved Wegovy HD 7.2 mg injection in March 2026 to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight and at least one weight-related condition. U.S. labeling also includes oral Wegovy tablets. The oral tablet is Wegovy, not an oral form of Ozempic [24].
Feature |
Berberine |
Ozempic / Wegovy (Semaglutide) |
|---|---|---|
Type
|
Plant alkaloid supplement
|
Prescription GLP-1 receptor agonist drug
|
Primary mechanism
|
Proposed AMPK-related and insulin-receptor signalling effects; mechanisms in humans remain incompletely established
|
GLP-1 receptor agonism; reduces appetite and energy intake and delays gastric emptying
|
Blood sugar reduction (HbA1c)
|
Yin et al. pilot (n=36): ~2.0 percentage-point reduction [1]. Pooled estimates: ~0.41 pp (7 RCTs; 756 participants; low certainty) [20] and ~0.63 pp (31 studies; 2,683 participants; mixed monotherapy/add-on comparisons) [21]. These are not directly interchangeable estimates.
|
Dose-dependent reductions in pivotal type 2 diabetes trials; magnitude varies with dose, baseline HbA1c, and background therapy [22].
|
Weight loss
|
~2 kg average in some meta-analyses [6]; 2026 JAMA RCT (n=337): berberine produced no significant additional benefit vs placebo on weight, BMI, waist circumference, visceral fat, or liver fat — both groups lost some weight [19]
|
STEP 1 trial: ~14.9% body weight over 68 weeks (Wegovy 2.4 mg obesity dose, not standard Ozempic dose) [13]. FDA approved Wegovy HD 7.2 mg March 2026.
|
FDA approval
|
Not FDA-approved to treat or prevent any disease
|
Ozempic: glycaemic control in adults with T2DM, with additional cardiovascular and kidney-risk indications for eligible patients [22]. Wegovy: chronic weight management, cardiovascular risk reduction in eligible adults, and accelerated approval for certain adults with MASH; oral and injectable formulations have product-specific indications [24].
|
Administration
|
Oral capsule / tablet
|
Ozempic: weekly subcutaneous injection. Wegovy: weekly injection or once-daily oral tablet. Wegovy HD 7.2 mg is an injectable formulation; the oral tablet is Wegovy, not oral Ozempic [22,24].
|
GI side effects
|
Nausea, diarrhoea, constipation, and abdominal discomfort; frequency and severity vary
|
Nausea, vomiting, diarrhoea, constipation, and other gastrointestinal effects; may be dose-related
|
Drug interactions
|
Potential CYP-mediated interactions; clinical significance varies by medication [15,16]
|
Review concomitant medicines and patient-specific risks against the current prescribing information [22,24]
|
Pregnancy safety
|
Avoid during pregnancy and breastfeeding; infant bilirubin concerns are noted by NCCIH [14]
|
Avoid during pregnancy; semaglutide prescribing information warns of potential fetal harm [24]
|
Long-term safety data
|
Limited long-term safety data
|
Multi-year clinical-outcomes data exist for selected indications; risks and evidence differ by product and population [22,24]
|
The bottom line: berberine is not a replacement for Ozempic or Wegovy. Berberine’s proposed metabolic pathways are not equivalent to GLP-1 receptor agonism; its weight findings are smaller and less consistent, and it lacks the cardiovascular-outcomes evidence available for semaglutide products. People prescribed semaglutide should not substitute berberine for it.
Berberine vs Metformin: A Clinical Perspective
The berberine–metformin comparison is a common question. Berberine is sometimes marketed as “natural metformin,” but that description is inaccurate: one is a dietary supplement with a limited evidence base, while the other is a prescription medicine supported by extensive clinical research.
Factor |
Berberine |
Metformin |
|---|---|---|
Mechanism
|
Proposed AMPK-related and other metabolic effects; insulin-receptor expression changes have been reported [12,28]
|
Primarily suppresses hepatic glucose production. The precise molecular pathways remain debated; complex I inhibition and AMPK activation are not established as the dominant mechanism at clinically relevant concentrations [26].
|
Blood glucose evidence
|
A small pilot reported a reduction similar in magnitude to metformin over 3 months, but it was not designed to prove equivalence [1].
|
Extensive long-term evidence, including UKPDS [23]
|
HbA1c reduction
|
Yin et al. pilot (n=36): ~2.0 pp [1]. Separate pooled analyses reported ~0.41 pp (7 RCTs; low certainty) [20] and ~0.63 pp (31 studies, including monotherapy and add-on comparisons) [21]. Different populations and comparators limit direct comparison.
|
Meta-analysis of 35 trials: 1.12 percentage-point reduction versus placebo (95% CI 0.92–1.32; I²=80%) [25]
|
LDL / cholesterol
|
Total cholesterol and triglyceride changes are more consistent; standalone LDL findings are mixed [8,10]
|
May produce modest secondary lipid changes; not prescribed primarily as a lipid-lowering medicine
|
Weight effect
|
Modest in some meta-analyses [6]; inconsistent across trials
|
Modest (similar modest range)
|
GI side effects
|
Nausea, diarrhoea (usually mild, often transient)
|
Nausea, diarrhoea (often significant at initiation; extended-release reduces this)
|
Vitamin B12 depletion
|
No established depletion effect
|
Associated with vitamin B12 deficiency on long-term use — 2026 ADA Standards of Care (Section 3) recommend periodic B12 monitoring [11a]
|
FDA approved for T2DM
|
No
|
Yes
|
Available without prescription
|
Yes (US)
|
No
|
Long-term cardiovascular data
|
No comparable long-term cardiovascular outcomes evidence
|
Long-term outcomes evidence includes UKPDS [23]
|
Metformin’s principal advantage is its much larger and longer evidence base, including long-term clinical outcomes data that berberine does not have [23].
The 2026 ADA Standards of Care emphasise individualised medication selection based on glucose targets, cardiovascular and kidney conditions, weight goals, adverse effects, and other patient factors. Pharmacotherapy should be initiated when type 2 diabetes is diagnosed unless contraindicated [11b]. For people prescribed metformin who tolerate it, berberine is not an evidence-based substitute. Anyone considering a supplement alongside diabetes treatment should discuss it with their healthcare professional.
Best Time to Take Berberine Supplements: Dosage Guide
Doses Used in Clinical Studies
A commonly studied regimen is berberine HCL 500 mg two or three times daily (1,000–1,500 mg total per day) [1,2]. NCCIH reports that clinical studies have used a broader range of 200–1,000 mg two or three times daily [14]. No regulatory authority has established a recommended dietary allowance or tolerable upper intake level for berberine. These are research doses, not universal prescriptions; an individual’s circumstances and medications require clinician review.
Most clinical trials administered berberine in divided doses, often two or three times daily. This describes the schedules studied; it does not establish a specific human half-life or prove that divided dosing maintains stable blood concentrations.
Berberine Before or After Meals?
The optimal time to take berberine has not been established in comparative clinical trials. Many studies administered divided doses with meals or around mealtimes [1,2]. Taking it with food may be easier for some people who experience gastrointestinal symptoms, while pre-meal use is sometimes proposed for post-meal glucose effects; neither approach is a universally validated protocol. Follow the product label and seek individual advice from a healthcare professional.
How Long to Take Berberine
Most clinical trials lasted approximately 3–6 months. HbA1c is commonly assessed after at least 8–12 weeks because it reflects average blood glucose over the preceding months; this is a research-assessment timeframe, not a minimum treatment recommendation. The appropriate duration should be determined with a clinician. Longer-term safety and efficacy data remain limited [14], so periodic reassessment is advisable, especially when berberine is used alongside prescription medication.
Dose / Day |
Protocol |
Evidence Base |
Notes |
|---|---|---|---|
500 mg × 3 (1,500 mg total)
|
Three divided doses, with or shortly before main meals
|
Yin et al. 2008 [1]; Lan et al. 2015 [2]
|
Most-studied research regimen. Divided schedules were used in trials; optimal interval is not established. Taking with food may be easier for some people to tolerate.
|
500 mg × 2 (1,000 mg total)
|
Two divided doses
|
Within NCCIH-reported clinical range [14]
|
Within studied range. Not an established GI tolerability protocol — taking fewer doses has not been validated as a solution for GI sensitivity.
|
Enhanced forms (lower dose)
|
Lower mg per dose for phytosome / DHB products
|
Limited — single small PK studies only [17,18]
|
No validated dose-conversion protocol established. Claims of equivalent clinical effects at lower doses are not confirmed by independent large RCTs. Follow product label.
|
Duration
|
Assess at 3–6 months per clinical trial design
|
Most trials lasted 3–6 months; longer-term safety data remain limited [14]
|
Time to measurable effect varies. Reassess periodically with healthcare provider. No official minimum duration established.
|
Side Effects and Downsides of Berberine Supplements
The main reported downsides of berberine supplements are gastrointestinal effects, including nausea, diarrhoea, constipation, and abdominal discomfort. These effects are more commonly reported at higher study doses (often 1,000–1,500 mg/day). Taking berberine with food may be easier for some people to tolerate, but it does not prevent side effects in everyone.
Reported Side Effects
Reported adverse effects include nausea, loose stools or diarrhoea, constipation, abdominal cramping or bloating, and, less commonly, headache. Some studies used gradual dose escalation, but no standardised titration schedule has been established as a proven way to prevent adverse effects. Persistent or severe symptoms should be discussed with a healthcare professional.
Is It Safe to Take Berberine Every Day?
Berberine has been tolerated in several clinical studies, but gastrointestinal effects are common and safety evidence varies by formulation, population, and treatment duration. Long-term safety remains insufficiently established. The 2026 JAMA randomised trial reported serious adverse events in 6 of 169 berberine participants versus 2 of 168 placebo participants; the difference was not statistically significant (P=.28) [19]. The trial also excluded people who could not tolerate berberine during a 30-day run-in period before randomisation, so its later tolerability findings may not represent everyone starting the supplement. A human probe-drug study found that repeated berberine administration inhibited CYP2D6, CYP2C9, and CYP3A4 activity [15].
The following groups need particular precautions and medical advice:
— Pregnant or breastfeeding women: NCCIH advises against berberine use during pregnancy and breastfeeding and against giving it to infants [14]. Berberine may increase the risk of harmful bilirubin accumulation in infants; it should not be used in these circumstances.
— Young children: Not recommended — insufficient safety data and bilirubin concerns.
— People scheduled for surgery: Disclose berberine use to your surgeon and anaesthesiologist before any planned procedure and follow their individualised advice on when to stop. No evidence-based berberine-specific discontinuation protocol has been established.
— People with significant hepatic impairment: Berberine has inhibited CYP3A4, CYP2C9, and CYP2D6 activity in a human probe-drug study [15]. This may alter the metabolism of some co-administered medicines. The study does not establish that berberine directly damages the liver or quantify risk in people with hepatic impairment; obtain individual medical advice.
— People with chronic kidney disease or a kidney transplant: Human pharmacokinetic and safety data in people with advanced chronic kidney disease or on dialysis are insufficient to establish a safe berberine dose. A 2026 review of berberine research in kidney disease describes predominantly experimental evidence and highlights the lack of high-quality human trials with kidney outcomes; it does not establish berberine as a treatment for chronic kidney disease or diabetic nephropathy [29]. People with kidney disease should not self-start berberine and should discuss it with their nephrologist or pharmacist, particularly if they take medicines with a narrow therapeutic range. A clinical study documented increased cyclosporine exposure in renal-transplant recipients taking berberine [16].
What Cannot Be Taken with Berberine?
In a randomised crossover study, healthy male volunteers took berberine 300 mg three times daily for two weeks before receiving probe drugs used to assess CYP enzyme activity. The study found reduced CYP2D6, CYP2C9, and CYP3A4 activity [15]. This demonstrates that berberine can affect the metabolism of some medicines, but the clinical significance varies by drug and cannot be inferred for every medication.
Omeprazole was also included in that study as a CYP2C19 probe drug. The investigators found no statistically significant differences in omeprazole pharmacokinetic parameters between the berberine and placebo periods. This small study did not demonstrate an omeprazole interaction, but it cannot establish that an interaction is impossible in every dose, formulation, or patient group [15].
Drug / Class |
Interaction Type |
Clinical Guidance |
|---|---|---|
Cyclosporine (immunosuppressant)
|
Confirmed clinical interaction — raises cyclosporine blood levels [16]
|
Wu et al. (2005) documented increased cyclosporine exposure with berberine in renal-transplant recipients. This is a clinically documented interaction. Do not start or combine berberine with cyclosporine without transplant-specialist management [16].
|
Metformin
|
Potential additional glucose lowering; clinical effect of routine co-use is not established
|
Both medicines may lower blood glucose, but shared or overlapping proposed pathways do not establish clinical synergy. Adjunctive studies do not establish routine combined use. Medical supervision and glucose monitoring are important, especially if insulin or sulfonylureas are also used.
|
Insulin / Sulfonylureas
|
Plausible additive blood-glucose-lowering risk
|
Berberine lowers blood glucose independently. Combined with insulin or sulfonylureas — which carry their own hypoglycaemia risk — a plausible additive effect exists. This is based on pharmacological reasoning; direct clinical trial evidence for this combination is limited. Blood glucose monitoring is warranted; discuss dose adjustments with your prescribing physician.
|
Warfarin (blood thinner)
|
Mechanistic concern — CYP2C9 inhibition may affect warfarin metabolism [15]
|
The concern is based on CYP2C9 inhibition; a warfarin-specific clinical interaction causing bleeding has not been established in controlled human trials. Disclose berberine use to the prescriber; INR monitoring may be considered by the clinician.
|
Losartan (blood pressure)
|
Human probe-drug evidence — CYP2C9 inhibition demonstrated using losartan [15]
|
In a healthy-volunteer probe study, berberine doubled the losartan/E-3174 ratio, indicating reduced CYP2C9 activity. This demonstrates a pharmacokinetic effect on a probe substrate, not clinical outcome data from chronic losartan co-use. Discuss with the prescriber [15].
|
Statins (CYP3A4-metabolised)
|
Mechanistic concern — potential for increased statin exposure [15]
|
CYP3A4 inhibition creates a potential interaction concern for simvastatin, lovastatin, and atorvastatin. Direct clinical outcome evidence for these combinations is limited. Pravastatin and rosuvastatin use different metabolic pathways. Review each medicine with the prescriber [15].
|
Blood pressure medications
|
Potential additional blood pressure lowering
|
Berberine may independently lower blood pressure in some studies. Combined with antihypertensives, blood pressure may fall further. Monitor blood pressure if combining.
|
Before planned surgery, disclose berberine use to the surgeon and anaesthesiologist. Follow the surgical team’s individual advice about whether and when to stop; no evidence-based berberine-specific discontinuation interval has been established.
How to Choose a Berberine Supplement
The quality of berberine supplements can vary. In the United States, dietary supplements are not approved by the FDA for safety and effectiveness before marketing in the same way as prescription medicines. Manufacturers remain responsible for product safety and accurate labelling, but independent verification of each product or batch is not universal. Third-party testing can provide additional assurance.
What to Look for in a Berberine Supplement
Ingredient quantity and labelling: Look for a product that clearly states the amount of berberine per capsule and identifies the specific form (e.g., berberine HCL). Transparent labelling of the actual berberine content — not a proprietary blend that obscures the quantity — is a basic quality indicator. Many clinical studies used 500 mg per capsule, which allows flexible dosing, but the amount per capsule is not itself a measure of quality.
Form of berberine: Standard berberine HCL is the form most represented in clinical trials. Phytosome and dihydroberberine formulations have small pharmacokinetic studies suggesting higher exposure, but this does not establish better gastrointestinal tolerability or equivalent clinical outcomes at lower doses. No validated dose-conversion protocol exists for these enhanced forms [17,18].
Affiliate disclosure: The product links below are affiliate links. Diabetes Knowledge Hub may earn a commission if you purchase through them. This does not change the price you pay and does not constitute a medical recommendation or guarantee of product effectiveness.
Dr. Berg Berberine
Add Dr. Berg Berberine with Ceylon Cinnamon to your daily wellness routine. This supplement combines berberine with Ceylon cinnamon in a convenient capsule formula.
Sports Research Berberine
Support your metabolic wellness routine with Sports Research Berberine. This non-GMO liquid softgel formula combines berberine with coconut oil for convenient daily use.
Note: Manufacturer GMP (Good Manufacturing Practice) certification confirms manufacturing process standards, but does not independently verify that a specific product batch contains exactly what its label claims. Third-party product testing (NSF, USP, ConsumerLab) provides stronger label-accuracy assurance.
Unnecessary additives: Avoid products with excessive fillers, artificial colours, or proprietary blends that obscure the actual berberine content.
Frequently Asked Questions
Berberine has been studied for lowering blood glucose and improving some measures of insulin sensitivity [1,2,20,21], reducing total cholesterol and triglycerides [3,8], and improving metabolic markers in women with PCOS [4,9]. Weight findings are inconsistent [5,6,19]. AMPK-related signalling is one proposed mechanism, but the mechanisms in humans are not fully established [12,28]. Berberine alone has not shown a statistically significant LDL reduction in the 2024 meta-analysis [8].
The evidence is mixed. Some meta-analyses report modest average weight reductions around 2 kg [6]. However, a 2026 randomised clinical trial of 337 participants found that berberine produced no significant additional benefit compared to placebo on body weight, BMI, waist circumference, or visceral adipose tissue — both groups experienced some weight reduction during the trial [19]. The belly-fat reduction claim is not reliably supported by current evidence, including the most recent large trial. Berberine is not established as a weight-loss treatment.
Berberine has been tolerated in some short-term clinical studies, but gastrointestinal effects are common and long-term safety remains uncertain. In the 2026 JAMA trial, serious adverse events were reported in 6 of 169 berberine participants and 2 of 168 placebo participants (P=.28); people unable to tolerate berberine during a 30-day run-in were excluded before randomisation [19]. Avoid use during pregnancy and breastfeeding, and discuss berberine with a clinician if you take prescription medicines.
No. Berberine and semaglutide work differently. Semaglutide is a GLP-1 receptor agonist; berberine is a plant alkaloid supplement with proposed metabolic actions that are not fully established in humans. The 14.9% weight reduction commonly cited for semaglutide comes from the STEP 1 trial of Wegovy 2.4 mg [13]. Berberine’s weight findings are smaller and inconsistent [5,6,19]. The products are not equivalent in mechanism, evidence, or effect size.
No universally validated optimal timing has been established. Clinical studies commonly used divided doses with meals or around mealtimes [1,2]. Taking berberine with food may be easier for some people to tolerate, while taking it shortly before meals is sometimes proposed for post-meal glucose effects; neither timing strategy has been proven best for everyone. Follow the product label and discuss timing with a healthcare professional.
The main downsides are gastrointestinal effects such as nausea, diarrhoea, constipation, and abdominal discomfort. Potential drug interactions through CYP enzyme inhibition are another concern [15], and long-term safety data are limited. Berberine is not FDA-approved to treat any condition, and evidence for claims such as belly-fat reduction and LDL lowering remains inconsistent [8,19].
Berberine may interact with prescription medicines. A clinical pharmacokinetic study in renal-transplant recipients found increased cyclosporine exposure with berberine co-administration [16]; this combination requires transplant-specialist management. A separate human probe-drug study demonstrated CYP2C9 inhibition using losartan as a probe, but did not establish clinical outcomes from chronic losartan co-use [15]. Potential interactions involving warfarin and some statins require medication-specific review. Additive glucose lowering with insulin or sulfonylureas is plausible but not well quantified in direct combination trials. Disclose berberine use to the prescribing clinician.
Berberine and metformin have been studied together in some research settings, but this does not establish the combination as routine treatment. Both may lower blood glucose, so additional glucose lowering is possible; the risk of hypoglycaemia is of particular concern when insulin or sulfonylureas are also used. Long-term metformin use is associated with vitamin B12 deficiency, for which the 2026 ADA Standards recommend assessment in appropriate patients [11a]. Do not combine supplements and prescription treatment without medical guidance.
A commonly studied berberine HCL regimen is 500 mg two or three times daily (1,000–1,500 mg total) [1,2]. NCCIH reports that clinical settings have used a broader range of 200–1,000 mg two or three times daily [14]. No official recommended dietary allowance or upper limit has been established. For phytosome or dihydroberberine products, follow the product label and obtain professional advice; lower doses have not been shown to produce equivalent clinical effects in large independent trials [17,18].
Berberine HCL (hydrochloride) is a common supplement form. “HCL” refers to the hydrochloride salt form. It is the form used in many clinical studies and is widely available. Its main limitation is low and variable oral bioavailability. Clinical trials commonly used divided doses, but the optimal dosing interval and a human half-life-based schedule have not been established.
Berberine has been studied in people with type 2 diabetes, and some trials and meta-analyses report reductions in blood-glucose measures [1,2,20,21]. However, the evidence has limitations and berberine is not an approved substitute for diabetes medication. It must not replace prescribed treatment. People considering it should discuss the risks with their clinician and monitor glucose as advised, particularly if taking insulin or a sulfonylurea. The 2026 ADA Standards recommend pharmacotherapy at diagnosis unless contraindicated [11b].
A quality-focused selection process should look for a clear amount of berberine per capsule, identification of the specific form, and independent testing from a recognised programme such as NSF, USP, or ConsumerLab. GMP certification relates to manufacturing practices but does not by itself verify the contents of a specific batch. Phytosome and dihydroberberine products have a smaller independent clinical evidence base than berberine HCL [17,18]; they should not be selected on the assumption that they are better tolerated.
References
References are numbered to match the in-text citations in this article. DOI and source links are provided where available.
- Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008;57(5):712–717. doi:10.1016/j.metabol.2008.01.013.
- Lan J, Zhao Y, Dong F, et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015;161:69–81. doi:10.1016/j.jep.2014.09.049.
- Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004;10(12):1344–1351. doi:10.1038/nm1135.
- Wei W, Zhao H, Wang A, et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. Eur J Endocrinol. 2012;166(1):99–105. doi:10.1530/EJE-11-0616.
- Amini MR, Sheikhhossein F, Naghshi S, et al. Effects of berberine and barberry on anthropometric measures: A systematic review and meta-analysis of randomized controlled trials. Complement Ther Med. 2020;49:102337. doi:10.1016/j.ctim.2020.102337.
- Asbaghi O, Ghanbari N, Shekari M, et al. The effect of berberine supplementation on obesity parameters, inflammation and liver enzymes: A systematic review and meta-analysis of randomized controlled trials. Clin Nutr ESPEN. 2020;38:43–49. doi:10.1016/j.clnesp.2020.04.010.
- Zeng XH, Zeng XJ, Li YY. Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 2003;92(2):173–176. doi:10.1016/S0002-9149(03)00533-2.
- Hernandez AV, Hwang J, Nasreen I, Sicignano D, Pasupuleti V, Snow-Caroti K, White CM. Impact of Berberine or Berberine Combination Products on Lipoprotein, Triglyceride and Biological Safety Marker Concentrations in Patients with Hyperlipidemia: A Systematic Review and Meta-Analysis. J Diet Suppl. 2024;21(2):242–259. doi:10.1080/19390211.2023.2212762.
- Xie L, Zhang D, Ma H, et al. The Effect of Berberine on Reproduction and Metabolism in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Evid Based Complement Alternat Med. 2019;2019:7918631. doi:10.1155/2019/7918631.
- Zhang Y, Li X, Zou D, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab. 2008;93(7):2559–2565. doi:10.1210/jc.2007-2404.
- American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1). Section 3: Prevention or Delay of Diabetes and Associated Comorbidities (vitamin B12 monitoring for long-term metformin users), doi:10.2337/dc26-S003; Section 9: Pharmacologic Approaches to Glycemic Treatment, doi:10.2337/dc26-S009.
- Zhang H, Wei J, Xue R, et al. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism. 2010;59(2):285–292. doi:10.1016/j.metabol.2009.07.029.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183.
- National Center for Complementary and Integrative Health (NCCIH). Diabetes and Dietary Supplements: What You Need to Know; In the News: Berberine; and Berberine and Weight Loss: What You Need to Know. These resources address reported clinical-use doses, pregnancy/breastfeeding and infant precautions, and limitations of the evidence. Diabetes and dietary supplements; Berberine safety note; Berberine and weight loss.
- Guo Y, Chen Y, Tan ZR, Klaassen CD, Zhou HH. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol. 2012;68(2):213–217. doi:10.1007/s00228-011-1108-2.
- Wu X, Li Q, Xin H, Yu A, Zhong M. Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study. Eur J Clin Pharmacol. 2005;61(8):567–572. doi:10.1007/s00228-005-0952-3.
- Petrangolini G, Corti F, Ronchi M, Arnoldi L, Allegrini P, Riva A. Development of an innovative berberine food-grade formulation with an ameliorated absorption: in vitro evidence confirmed by healthy human volunteers pharmacokinetic study. Evid Based Complement Alternat Med. 2021;2021:7563889. doi:10.1155/2021/7563889.
- Moon JM, Ratliff KM, Hagele AM, Stecker RA, Mumford PW, Kerksick CM. Absorption kinetics of novel berberine formulations in healthy humans. Nutrients. 2022;14(1):124. doi:10.3390/nu14010124.
- Lei L, Wang B, Zhao L, et al. Berberine and adiposity in diabetes-free individuals with obesity and MASLD: a randomized clinical trial. JAMA Netw Open. 2026;9(1):e2554152. doi:10.1001/jamanetworkopen.2025.54152.
- Zhao JV, Huang X, Zhang J, Chan YH, Tse HF, Blais JE. Overall and Sex-Specific Effect of Berberine on Glycemic and Insulin-Related Traits: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Nutr. 2023;153(10):2939–2950. doi:10.1016/j.tjnut.2023.08.016. The berberine-versus-placebo analysis reported an HbA1c mean difference of approximately −0.41 percentage points (7 RCTs; 756 participants; low-certainty evidence; I²=73%).
- Xie W, Su F, Wang G, Peng Z, Xu Y, Zhang Y, Xu N, Hou K, Hu Z, Chen Y, Chen R. Glucose-lowering effect of berberine on type 2 diabetes: A systematic review and meta-analysis. Front Pharmacol. 2022;13:1015045. doi:10.3389/fphar.2022.1015045. The HbA1c analysis included 31 studies and 2,683 participants and reported a weighted mean difference of approximately −0.63 percentage points; included comparisons covered berberine alone and add-on regimens.
- U.S. National Library of Medicine. DailyMed: Ozempic (semaglutide) injection, solution—current prescribing information. Label updated June 1, 2026. Current DailyMed prescribing information.
- UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854–865. doi:10.1016/S0140-6736(98)07037-8.
- U.S. Food and Drug Administration. Wegovy (semaglutide) injection and tablets, including Wegovy HD 7.2 mg: current prescribing information. 2026. FDA prescribing information (PDF).
- Hirst JA, Farmer AJ, Ali R, Roberts NW, Stevens RJ. Quantifying the effect of metformin treatment and dose on glycemic control. Diabetes Care. 2012;35(2):446–454. doi:10.2337/dc11-1465. Metformin monotherapy reduced HbA1c by 1.12 percentage points versus placebo (95% CI 0.92–1.32; I²=80%).
- LaMoia TE, Shulman GI. Cellular and molecular mechanisms of metformin action. Endocr Rev. 2021;42(1):77–96. doi:10.1210/endrev/bnaa023.
- Nie Q, Li M, Huang C, et al. The clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver disease: a meta-analysis and systematic review. J Transl Med. 2024;22:225. doi:10.1186/s12967-024-05011-2. The review included 10 RCTs and 811 participants; it reported changes in several surrogate markers but noted heterogeneity and inconclusive clinical evidence.
- Askari VR, Khosravi K, Baradaran Rahimi V, Garzoli S. A mechanistic review on how berberine use combats diabetes and related complications: molecular, cellular, and metabolic effects. Pharmaceuticals (Basel). 2024;17(1):7. doi:10.3390/ph17010007. This review discusses proposed AMPK and GLUT4 pathways across cellular, animal, and clinical research; it should not be interpreted as proof that these mechanisms are established in humans.
- Wang L, Guo R, Feng X, Tang L. Research Progress of Berberine in Kidney Disease: Targeting Mitochondria and Ferroptosis. iNew Medicine. Published online September 19, 2026. doi:10.1002/inm3.70085. This review primarily discusses preclinical mechanisms and highlights the limited human clinical-outcome evidence for berberine in kidney disease.
Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Berberine is a dietary supplement, not an FDA-approved treatment for diabetes or any other disease. Do not start, stop, or change prescribed medication because of this article. Consult a qualified healthcare professional or pharmacist before using berberine, particularly if you take prescription medicines, have liver or kidney disease, are pregnant or breastfeeding, or are scheduled for surgery. Seek urgent medical care for a medical emergency.